Janssen Pharmaceutica Nv

Chaozhong Cai

Wei He

Henry Joseph Breslin

Robert William Kavash

Zhihua Sui

Mark J Macielag

Peter J Connolly

Philip Michael Pitis

Scott L Dax

Xuqing Zhang

Li Liu

Haiyan Bian

Steven J Coats

Bart L DeCorte

Bin Benjamin Zhu

Yue-Mei Zhang

Shu-Chen Lin

Gilles C Bignan

David F McComsey

James C Lanter

Thomas P Markotan

Bart L De Corte

Heather Rae Hufnagel

Fu-An Kang

Fu An Kang

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R, G, and Q are defined herein;and wherein R, R, R, Rand G, are defined herein.

GPR120 agonists for the treatment of type II diabetes

The present invention is directed to novel opioid receptor modulators of Formula (I).  The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

Compounds as opioid receptor modulators

The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.

The present invention comprises compounds of Formula (I). wherein: R, R, R, R, R, Zand Zare as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Octahydro-cyclopentapyrrolyl antagonists of CCR2

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R, R, R, R, and Y are defined herein.

4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R, R, R, and L, A, and Rare defined herein.

Pyrimidine compounds as delta opioid receptor modulators

The present invention comprises compounds of Formula (I). wherein: X, R, R, R, and Rare as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2

The present invention comprises compounds of Formula I. wherein: R, R, R, R, Rand X are as defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is uveitis, including acute, recurring or chronic uveitis. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Piperidyl acrylamide antagonists of CCR2

Growing community of inventors

North Wales, PA, United States of America

Chaozhong Cai